For research use only. Not for therapeutic Use.
Ceftizoxime Sodium（Cat No.:I004573）is a third-generation cephalosporin antibiotic effective against a broad range of gram-negative and some gram-positive bacteria. It works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Ceftizoxime Sodium is commonly used in the treatment of respiratory tract infections, urinary tract infections, skin infections, and septicemia. Known for its stability against beta-lactamase enzymes, it provides reliable activity against resistant bacterial strains. Administered via injection, Ceftizoxime Sodium is valuable in hospital settings for managing moderate to severe infections with a broad antimicrobial spectrum.
| Catalog Number | I004573 |
| CAS Number | 68401-82-1 |
| Molecular Formula | C13H12N5NaO5S2 |
| Purity | ≥95% |
| Target | Penicillin-binding protein (PBP) |
| Solubility | DMSO: 15 mg/mL |
| Storage | -20°C |
| IUPAC Name | sodium;(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| InChI | InChI=1S/C13H13N5O5S2.Na/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18;/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22);/q;+1/p-1/b17-7-;/t8-,11-;/m1./s1 |
| InChIKey | ADLFUPFRVXCDMO-LIGXYSTNSA-M |
| SMILES | CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=CCS3)C(=O)[O-].[Na+] |
| Reference | </br>1:Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium. Türkeş C, Söyüt H, Beydemir Ş.J Enzyme Inhib Med Chem. 2015;30(4):622-8. doi: 10.3109/14756366.2014.959511. Epub 2014 Dec 18. PMID: 25519764 </br>2:Structural identification and characterization of impurities in ceftizoxime sodium. Bharathi Ch, Prasad ChS, Bharathi DV, Shankar R, Rao VJ, Dandala R, Naidu A.J Pharm Biomed Anal. 2007 Jan 17;43(2):733-40. Epub 2006 Sep 6. PMID: 16950586 </br>3:Stability of metronidazole and ceftizoxime sodium in ready-to-use metronidazole bags stored at 4 and 25 degrees C. Nahata MC, Edmonds JJ, Morosco RS.Am J Health Syst Pharm. 1996 May 1;53(9):1046-8. No abstract available. PMID: 8744468 </br>4:Stability of ceftizoxime sodium, ceftriaxone sodium, and ceftazidime with metronidazole in ready-to-use metronidazole bags. Rivers TE, Webster AA.Am J Health Syst Pharm. 1995 Nov 15;52(22):2568-70. No abstract available. PMID: 8590243 </br>5:Visual compatibility of ceftizoxime sodium in four electrolyte injections. Swenson E, Gooch WM 3rd, Higbee MD.Am J Hosp Pharm. 1986 Sep;43(9):2242-4. No abstract available. PMID: 3766586 </br>6:Influence of human serum on bactericidal activity of ceftizoxime sodium. Watanabe K, Kin R, Murakami M, Kondo M.Chemotherapy. 1986;32(2):113-7. PMID: 3516590 </br>7:Particle formation of ceftizoxime sodium injections. Carlson GH, Matzke GR.Am J Hosp Pharm. 1985 Dec;42(12):2651-2. No abstract available. PMID: 3866491 </br>8:[Clinical investigation of ceftizoxime sodium suppositories in pediatric infections]. Tomimasu K, Hayashi K, Tsuji Y.Jpn J Antibiot. 1985 Oct;38(10):3065-9. Japanese. PMID: 3908730 </br>9:[Clinical investigation of ceftizoxime sodium suppositories in the field of pediatrics]. Sato T, Ueda K, Kuroiwa T.Jpn J Antibiot. 1985 Oct;38(10):3057-64. Japanese. PMID: 3866092 </br>10:Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitin sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions. Bosso JA, Townsend RJ.Am J Hosp Pharm. 1985 Oct;42(10):2211-4. PMID: 3864367 |
